TransMedics Group WKN: A2PH5P ISIN: US89377M1099 Kürzel: TMDX Forum: Aktien Thema: Hauptdiskussion

TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Heart System https://stockhouse.com/news/press-releases/2021/04/06/transmedics-stock-trading-halted-today-fda-advisory-committee-to-review ...The U.S. Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee is meeting today to review TransMedics' Organ Care System™ (OCS) Heart System. The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve a donated heart in a near-physiologic, beating and perfused state, while continually monitoring and optimizing heart function for eventual transplantation into the recipient. The Advisory Committee meeting is scheduled for 9:00 a.m. ET . ...

👍

I told you all

Analyst Actions: Canaccord Adjusts TransMedics Group's Price Target to $79 from $46, Keeps Buy Rating https://pub.webull.com/us/news-html/acf754c4e8af4092a8bf660a22d736fb.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en

TransMedics Group Q4 EPS $(0.23) Beats $(0.25) Estimate, Sales $7.60M Beat $6.04M Estimate https://pub.webull.com/us/news-html/62acd24fa6404ffb8d89231b49b30dac.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en TransMedics Group (NASDAQ:TMDX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.25) by 8 percent. This is a 46.51 percent increase over losses of $(0.43) per share from the same period last year. The company reported quarterly sales of $7.60 million which beat the analyst consensus estimate of $6.04 million by 25.83 percent. This is a 25.47 percent increase over sales of $6.06 million the same period last year.

TransMedics Reports Fourth Quarter and Full Year 2020 Financial Results https://www.prnewswire.com/news-releases/transmedics-reports-fourth-quarter-and-full-year-2020-financial-results-301238951.html ... Recent Highlights • Net revenue of $7.6 million in the fourth quarter of 2020, representing 26% growth compared to the fourth quarter of 2019 • Expanded the National OCS Program to include 5 new U.S. regions • Initiated the OCS Heart DCD CAP program in 25 U.S. heart transplant centers • Completed enrollment of the OCS Liver PROTECT CAP first tranche of 74 patients • Appointed Merilee Raines to Board of Directors • Announced scheduling of OCS Heart FDA Advisory Panel Committee Meeting on April 6, 2021 ...

https://www.prnewswire.com/news-releases/transmedics-announces-scheduling-of-ocs-heart-fda-advisory-committee-meeting-301237810.html?fbclid=IwAR0yiqxOp_dCLuQ4Y9cN27mo566KyX1mon9luIOG5oy-nkhD6qOtCJpQuAI

Die FDA Zulassung ist nahe

UK doctors pioneer use of 'heart in a box' transplant technique in children https://www.theguardian.com/society/2021/feb/21/uk-doctors-pioneer-use-of-heart-in-a-box-transplant-technique-in-children Procedure previously deemed suitable only for adults saved the lives of six young patients last year

@Tommy87 wie bist du auf die Aktie aufmerksam geworden

https://pub.webull.com/us/news-html/b13478f55e6c402a89af51abb7978e52.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en TransMedics Up Nearly 27%, on Track for Record Percent Increase and Record High Close

🍀

Direkt mal vorbeigeschaut 👀

Wer das liest hat sehr wahrscheinlich den größten run bereits verpasst. Man wird in der NYT oder sonstigen Portalen davon lesen wenn es bereits ein small cap oder middle cap ist, da ist das schon längst ein multi bagger...Ich bin seit $14 dabei

Boom Ausbruch

Interessante Technik, fliegt noch unter dem radar aber wenn sie die zulassung bekommen dann geht's ab, null Wettbewerb hier und noch Menschenleben retten